KRAS inhibitor-10 (oral administration; 20 mg/kg; BID; 27 days) is safe and tolerate for the bearing mice. KRAS inhibitor-10 demonstrates significant oral anti-tumor activities in vivo. And the tumor growth inhibition (TGI) value is 48.22% for KRAS inhibitor-10.
参考文献:
1. Miguel VEGA GARCÍA, et al. Tetrahydroisoquinoline compounds. Patent wo2021002165